Chief Legal Officer, Secretary and Compliance Officer · ZEVRA THERAPEUTICS, INC. (ZVRA)

Rahsaan Thompson

FY2025 is the first fiscal year CompBrief holds for Rahsaan Thompson as a named executive officer of ZEVRA THERAPEUTICS; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Velarion Intel: free for 3 days, no card →

Total disclosed compensation, FY2025

$1,571,374

3rd of 3 named executive officers at Zevra Therapeutics by FY2025 total.

3 named officers on file for ZEVRA THERAPEUTICS, FY2025

See an example →

What this number hides

The filing gives the total. ZEVRA THERAPEUTICS’s full Executive Compensation Report gives every award, the disclosed peer set and what the total leaves out — the pair adds the board’s.

Compensation figures as of the proxy filed April 20, 2026 (DEF 14A).

Free

Get Rahsaan Thompson’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Also free: The Pay Desk, the weekly executive pay briefing.

Or track Rahsaan Thompson and every company like it: Velarion Intel, free for 3 days, no card →

Rahsaan Thompson compensation by year

ZEVRA THERAPEUTICS Summary Compensation Table · the one fiscal year held
In US dollars, as ZEVRA THERAPEUTICS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2025
Salary$466,667
Bonus$50,000
Stock awards$272,680
Option awards$545,360
Non-equity incentive$178,600
Pension and deferred compensation$0
All other$58,067
Total$1,571,374

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: ZEVRA THERAPEUTICS, INC. DEF 14A filed April 20, 2026, accession 0001434647-26-000025, and prior-year filings. Open the filing on EDGAR.

How this page was built: the ZEVRA THERAPEUTICS, INC. filed document, accession 0001434647-26-000025. Every figure is read from that document and cited to the page and table it appears in. Filed April 20, 2026.

Equity holdings

unvested awards at FY2025 year-end
TypeUnvested unitsValue at year-endExercise price
PSU133,334$1,194,673—
PSU34,000$304,640—
PSU20,000$179,200—
Option68,000—$8.02

Per the Outstanding Equity Awards at Fiscal Year-End table in ZEVRA THERAPEUTICS, INC.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.

ZEVRA THERAPEUTICS’s named executive officers, FY2025

as the company reported each
Named executive officerRoleFY2025 total
R. LaDuane CliftonFormer Chief Financial Officer and Treasurer$3,821,924
Neil McFarlanePresident, Chief Executive Officer and Director$3,782,042
Rahsaan Thompson · this pageChief Legal Officer, Secretary and Compliance Officer$1,571,374

The full ZEVRA THERAPEUTICS compensation record

free company brief

This page is one person within ZEVRA THERAPEUTICS's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order ZEVRA THERAPEUTICS's full Executive Compensation Report with peer benchmarking.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are ZEVRA THERAPEUTICS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Order ZVRA

Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.

Receipt, invoice, and report delivery. Guest checkout, no account required, secure payment by Stripe.

Rahsaan Thompson's compensation dossier